Results 261 to 270 of about 21,287,561 (278)

Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma

Bioorganic Chemistry, 2021
Ibrahim H Eissa, Ahmed M Metwaly, Amany Belal   +2 more
exaly  

VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis

Cell Research, 2010
Luqing Zhang, , Bin Shen
exaly  

Relevanz des VEGFR-1 Aktivierungsweges für die Kolonkarzinommetastasierung

Zeitschrift für Gastroenterologie, 2015
N Simiantonaki, C Jayasinghe, C Kirkpatrick   +2 more
openaire   +1 more source

The role of the VEGF-C/VEGFR-3 axis in cancer progression

British Journal of Cancer, 2006
C-J Yen, Mien-Chie Hung, M-L Kuo
exaly  

Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity

Biochemical and Biophysical Research Communications, 2004
Jean-Pascal Herault, Benoit Favier, Cecile Cassan   +2 more
exaly  

Functional significance of VEGFR‐2 on ovarian cancer cells

International Journal of Cancer, 2009
Whitney A Spannuth, Nicholas B Jennings, Lingegowda S Mangala   +2 more
exaly  

Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors

European Journal of Medicinal Chemistry, 2016
Yungen Xu, Li-Ping Sun
exaly  

Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors

European Journal of Medicinal Chemistry, 2014
Maria Leticia De Castro Barbosa, Lidia Moreira Lima, Roberta Tesch   +2 more
exaly  

Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2

European Journal of Medicinal Chemistry, 2017
Yungen Xu, Li-Ping Sun
exaly  

Comparative Structure‐Function Analysis of VEGFR‐1 and VEGFR‐2

Annals of the New York Academy of Sciences, 2003
Rosana D Meyer, Nader Rahimi
exaly